RhASA
( DrugBank: - / KEGG DRUG: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 19 | ライソゾーム病 | 20 |
19. ライソゾーム病
臨床試験数 : 899 / 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182
Showing 1 to 10 of 20 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2018-003291-12-IT (EUCTR) | 16/10/202020201016 | 21/10/202020201021 | Research study to determine the effects of an investigational drug, SHP611 on patients with with Late Infantile Metachromatic Leukodystrophy (MLD) specially the gross motor function, using the Gross Motor FunctionClassification in Metachromatic Leukodystrophy (GMFC-MLD) compared with matched historical control data in children with MLD. Research study to determine the effects of an investigational drug, SHP611 on patients with with Lat ... | A Global, Multicenter, Open-label, Matched Historical Control Study of Intrathecal SHP611 in Subjects with Late Infantile Metachromatic Leukodystrophy - ---- A Global, Multicenter, Open-label, Matched Historical Control Study of Intrathecal SHP611 in Subject ... | Late Metachromatic Leukodystrophy (MLD) MedDRA version: 20.0;Level: PT;Classification code 10067609;Term: Metachromatic leukodystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Late Metachromatic Leukodystrophy (MLD) MedDRA version: 20.0;Level: PT;Classification code 10067609; ... | Trade Name: -- Product Name: --- Product Code: [SHP611] INN or Proposed INN: Recombinant Human Arylsulfatase A (rhASA) Other descriptive name: RECOMBINANT HUMAN ARYLSULFATASE A Trade Name: -- Product Name: --- Product Code: [SHP611] INN or Proposed INN: Recombinant Human Arylsulf ... | SHIRE HUMAN GENETIC THERAPIES, INC | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 42 | Phase 2 | United States;France;Canada;Spain;Brazil;Belgium;Israel;Netherlands;Germany;United Kingdom;Japan;Italy United States;France;Canada;Spain;Brazil;Belgium;Israel;Netherlands;Germany;United Kingdom;Japan;Ita ... | ||
| 2 | EUCTR2012-003775-20-IT (EUCTR) | 20/03/201720170320 | 15/03/201720170315 | A safety and efficacy extension of study HGT-MLD-070 in Children with Metachromatic Leukodystrophy recieving enzyme (HGT-1110) replacement by intrathecal injection A safety and efficacy extension of study HGT-MLD-070 in Children with Metachromatic Leukodystrophy r ... | An Open-label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal Administration of HGT-1110 in Patients with Metachromatic Leukodystrophy An Open-label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal ... | Treatment of Metachromatic Leukodystrophy MedDRA version: 19.1;Level: PT;Classification code 10067609;Term: Metachromatic leukodystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Treatment of Metachromatic Leukodystrophy MedDRA version: 19.1;Level: PT;Classification code 1006760 ... | Product Code: SHP611 INN or Proposed INN: Not available Other descriptive name: Recombinant Human Arylsulfatase A (rhASA) Product Code: SHP611 INN or Proposed INN: Not available Other descriptive name: Recombinant Human Aryl ... | Shire Human Genetics Therapies Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 24 | Phase 1;Phase 2 | France;Czech Republic;Brazil;Denmark;Australia;Germany;Japan;United Kingdom;Italy | ||
| 3 | EUCTR2012-003775-20-GB (EUCTR) | 25/04/201620160425 | 06/06/201620160606 | A safety and efficacy extension of study HGT-MLD-070 in Children with Metachromatic Leukodystrophy recieving enzyme (HGT-1110) replacement by intrathecal injection A safety and efficacy extension of study HGT-MLD-070 in Children with Metachromatic Leukodystrophy r ... | An Open-label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal Administration of HGT-1110 in Patients with Metachromatic Leukodystrophy An Open-label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal ... | Treatment of Metachromatic Leukodystrophy MedDRA version: 20.0;Level: PT;Classification code 10067609;Term: Metachromatic leukodystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Treatment of Metachromatic Leukodystrophy MedDRA version: 20.0;Level: PT;Classification code 1006760 ... | Product Code: SHP611 INN or Proposed INN: Not available Other descriptive name: Recombinant Human Arylsulfatase A (rhASA) Product Code: SHP611 INN or Proposed INN: Not available Other descriptive name: Recombinant Human Aryl ... | Shire Human Genetics Therapies Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 24 | Phase 1;Phase 2 | France;Czech Republic;Brazil;Denmark;Australia;Germany;Japan;Italy;United Kingdom | ||
| 4 | EUCTR2012-003775-20-CZ (EUCTR) | 06/06/201420140606 | 14/02/201420140214 | A safety and efficacy extension of study HGT-MLD-070 in Children with Metachromatic Leukodystrophy recieving enzyme (HGT-1110) replacement by intrathecal injection A safety and efficacy extension of study HGT-MLD-070 in Children with Metachromatic Leukodystrophy r ... | An Open-label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal Administration of HGT-1110 in Patients with Metachromatic Leukodystrophy An Open-label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal ... | Treatment of Metachromatic Leukodystrophy MedDRA version: 20.0;Level: PT;Classification code 10067609;Term: Metachromatic leukodystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Treatment of Metachromatic Leukodystrophy MedDRA version: 20.0;Level: PT;Classification code 1006760 ... | Product Name: SHP611 INN or Proposed INN: Not available Other descriptive name: Recombinant Human Arylsulfatase A (rhASA) Product Name: SHP611 INN or Proposed INN: Not available Other descriptive name: Recombinant Human Aryl ... | Shire Human Genetics Therapies Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 24 | Phase 1;Phase 2 | France;Czech Republic;Brazil;Denmark;Australia;Germany;United Kingdom;Japan;Italy | ||
| 5 | EUCTR2012-003775-20-DE (EUCTR) | 11/09/201320130911 | 14/12/201220121214 | A safety and efficacy extension of study HGT-MLD-070 in Children with Metachromatic Leukodystrophy recieving enzyme (HGT-1110) replacement by intrathecal injection A safety and efficacy extension of study HGT-MLD-070 in Children with Metachromatic Leukodystrophy r ... | An Open-label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal Administration of HGT-1110 in Patients with Metachromatic Leukodystrophy An Open-label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal ... | Treatment of Metachromatic Leukodystrophy MedDRA version: 20.0;Level: PT;Classification code 10067609;Term: Metachromatic leukodystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Treatment of Metachromatic Leukodystrophy MedDRA version: 20.0;Level: PT;Classification code 1006760 ... | Product Code: SHP611 INN or Proposed INN: Not available Other descriptive name: Recombinant Human Arylsulfatase A (rhASA) Product Code: SHP611 INN or Proposed INN: Not available Other descriptive name: Recombinant Human Aryl ... | Shire Human Genetics Therapies Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 24 | Phase 1;Phase 2 | France;Czechia;Czech Republic;Brazil;Denmark;Australia;Germany;United Kingdom;Italy;Japan | ||
| 6 | EUCTR2012-003775-20-DK (EUCTR) | 30/04/201320130430 | 21/12/201220121221 | A safety and efficacy extension of study HGT-MLD-070 in Children with Metachromatic Leukodystrophy recieving enzyme (HGT-1110) replacement by intrathecal injection A safety and efficacy extension of study HGT-MLD-070 in Children with Metachromatic Leukodystrophy r ... | An Open-label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal Administration of HGT-1110 in Patients with Metachromatic Leukodystrophy An Open-label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal ... | Treatment of Metachromatic Leukodystrophy MedDRA version: 20.0;Level: PT;Classification code 10067609;Term: Metachromatic leukodystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Treatment of Metachromatic Leukodystrophy MedDRA version: 20.0;Level: PT;Classification code 1006760 ... | Product Code: SHP611 INN or Proposed INN: Not available Other descriptive name: Recombinant Human Arylsulfatase A (rhASA) Product Code: SHP611 INN or Proposed INN: Not available Other descriptive name: Recombinant Human Aryl ... | Shire Human Genetics Therapies Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 24 | Phase 1;Phase 2 | France;Czechia;Czech Republic;Brazil;Australia;Denmark;Germany;United Kingdom;Italy;Japan | ||
| 7 | EUCTR2011-002044-28-DE (EUCTR) | 14/06/201220120614 | 28/06/201120110628 | A safety and efficacy study in Children with Metachromatic Leukodystrophy recieving enzyme (HGT-1110) replacement by intrathecal injection A safety and efficacy study in Children with Metachromatic Leukodystrophy recieving enzyme (HGT-1110 ... | A Phase I/II, Multicenter, Open-label, Dose Escalation Study of HGT-1110 Administered Intrathecally in Children with Metachromatic Leukodystrophy A Phase I/II, Multicenter, Open-label, Dose Escalation Study of HGT-1110 Administered Intrathecally ... | Treatment of Metachromatic Leukodystrophy MedDRA version: 19.0;Level: PT;Classification code 10067609;Term: Metachromatic leukodystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Treatment of Metachromatic Leukodystrophy MedDRA version: 19.0;Level: PT;Classification code 1006760 ... | Product Code: HGT-1110 INN or Proposed INN: N/A Other descriptive name: Recombinant Human Arylsulfatase A (rhASA, Product Code: HGT-1110 INN or Proposed INN: N/A Other descriptive name: Recombinant Human Arylsulfatas ... | Shire Human Genetics Therapies Inc | NULL | Not Recruiting | Female: yes Male: yes | 24 | Phase 1;Phase 2 | France;Brazil;Denmark;Australia;Germany;Japan | ||
| 8 | EUCTR2011-002044-28-DK (EUCTR) | 25/11/201120111125 | 16/08/201120110816 | A safety and efficacy study in Children with Metachromatic Leukodystrophy recieving enzyme (HGT-1110) replacement by intrathecal injection A safety and efficacy study in Children with Metachromatic Leukodystrophy recieving enzyme (HGT-1110 ... | A Phase I/II, Multicenter, Open-label, Dose Escalation Study of HGT-1110 Administered Intrathecally in Children with Metachromatic Leukodystrophy A Phase I/II, Multicenter, Open-label, Dose Escalation Study of HGT-1110 Administered Intrathecally ... | Treatment of Metachromatic Leukodystrophy MedDRA version: 19.0;Level: PT;Classification code 10067609;Term: Metachromatic leukodystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Treatment of Metachromatic Leukodystrophy MedDRA version: 19.0;Level: PT;Classification code 1006760 ... | Product Code: HGT-1110 INN or Proposed INN: N/A Other descriptive name: Recombinant Human Arylsulfatase A (rhASA, Product Code: HGT-1110 INN or Proposed INN: N/A Other descriptive name: Recombinant Human Arylsulfatas ... | Shire Human Genetics Therapies Inc | NULL | Not Recruiting | Female: yes Male: yes | 24 | Phase 1;Phase 2 | France;Brazil;Australia;Denmark;Germany;Japan | ||
| 9 | EUCTR2008-000084-41-BE (EUCTR) | 03/03/201020100303 | 15/12/200920091215 | A multi-center open label extension study of HGT-1111 (Recombinant Human Arylsulfatase A or rhASA) treatment in patients with Late Infantile Metachromatic Leukodystrophy (MLD) A multi-center open label extension study of HGT-1111 (Recombinant Human Arylsulfatase A or rhASA) t ... | A multi-center open label extension study of HGT-1111 (Recombinant Human Arylsulfatase A or rhASA) treatment in patients with Late Infantile Metachromatic Leukodystrophy (MLD) A multi-center open label extension study of HGT-1111 (Recombinant Human Arylsulfatase A or rhASA) t ... | Metachromatic Leukodystrophy (MLD) in late infantile patients MedDRA version: 9.1;Level: LLT;Classification code 10024381;Term: Leukodystrophy Metachromatic Leukodystrophy (MLD) in late infantile patients MedDRA version: 9.1;Level: LLT;Classif ... | Product Name: HGT-1111 Product Code: rhASA Other descriptive name: recombinant human arylsulfatase A | Shire Human Genetic Therapies Inc | NULL | Not Recruiting | Female: yes Male: yes | 18 | Phase 2 | France;Belgium;Denmark;Italy | ||
| 10 | EUCTR2008-000084-41-FR (EUCTR) | 01/12/200920091201 | 05/08/200920090805 | A multi-center open label extension study of HGT-1111 (Recombinant Human Arylsulfatase A or rhASA) treatment in patients with Late Infantile Metachromatic Leukodystrophy (MLD) A multi-center open label extension study of HGT-1111 (Recombinant Human Arylsulfatase A or rhASA) t ... | A multi-center open label extension study of HGT-1111 (Recombinant Human Arylsulfatase A or rhASA) treatment in patients with Late Infantile Metachromatic Leukodystrophy (MLD) A multi-center open label extension study of HGT-1111 (Recombinant Human Arylsulfatase A or rhASA) t ... | Metachromatic Leukodystrophy (MLD) in late infantile patients MedDRA version: 9.1;Level: LLT;Classification code 10024381;Term: Leukodystrophy Metachromatic Leukodystrophy (MLD) in late infantile patients MedDRA version: 9.1;Level: LLT;Classif ... | Product Name: HGT-1111 Product Code: rhASA Other descriptive name: recombinant human arylsulfatase A | Shire Human Genetic Therapies Inc | NULL | Not Recruiting | Female: yes Male: yes | 18 | Phase 2 | France;Belgium;Denmark;Italy |